Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: and neckhead andstagecancerradiation
  Phrases that lowered it: painnasaltrialcriteriadisorder
• Sponsor's past termination rate: 45.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: 21 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 16.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 505368 (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 105322 (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 75.3% (lowers risk) · Drug's FDA history
• Primary purpose: supportive care (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer NCT03269344 · started 2017 · scored riskier than 64% of active trials completed
• Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation NCT02531906 · started 2015 · scored riskier than 88% of active trials completed
• Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy NCT00790322 · started 2008 · scored riskier than 89% of active trials completed
• Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation NCT02630004 · started 2015 · scored riskier than 76% of active trials completed
• A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer NCT02013050 · started 2013 · scored riskier than 95% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.